title: Post-transplant lymphoproliferative disorder following cytomegalovirus reactivation in a lung recipient.
abstract: Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication after lung transplantation, for which several risk factors including pretransplant seronegativity for Epstein-Barr virus are known. However, the impact of cytomegalovirus on PTLD remains to be determined. Here, we describe a case of Epstein-Barr virus-associated polymorphic PTLD that developed shortly after treatment for cytomegalovirus reactivation in a lung transplant recipient who was preoperatively seropositive for both cytomegalovirus and Epstein-Barr virus.
authors.affiliation: Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
authors.forename: Akihiro
authors.initials: A
authors.lastname: Aoyama
authors.forename: Mitsugu
authors.initials: M
authors.lastname: Omasa
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Kondo
authors.forename: Fengshi
authors.initials: F
authors.lastname: Chen
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Date
authors.forename: Toru
authors.initials: T
authors.lastname: Bando
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage; D001706:Biopsy; D003587:Cytomegalovirus / Q000472:pathogenicity*; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000188:drug therapy / Q000821:virology*; D020031:Epstein-Barr Virus Infections / Q000175:diagnosis / Q000188:drug therapy / Q000821:virology*; D015774:Ganciclovir / Q000008:administration & dosage; D004854:Herpesvirus 4, Human / Q000472:pathogenicity*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016040:Lung Transplantation / Q000009:adverse effects*; D008232:Lymphoproliferative Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000821:virology*; D008297:Male; D008875:Middle Aged; D015899:Tomography, Emission-Computed, Single-Photon; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage; D014775:Virus Activation
chemical_list: D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D014740:Vidarabine; D015774:Ganciclovir
references.citation: Chest. 2003 Oct;124(4):1242-9
references.pmid: 14555552
references.citation: J Heart Lung Transplant. 2003 May;22(5):505-14
references.pmid: 12742411
references.citation: J Heart Lung Transplant. 2005 Jun;24(6):671-9
references.pmid: 15949726
references.citation: Transplantation. 2002 Jan 15;73(1):100-4
references.pmid: 11792987
references.citation: Pediatr Transplant. 2006 Aug;10(5):613-6
references.pmid: 16856999
references.citation: J Infect Dis. 1997 Dec;176(6):1462-7
references.pmid: 9395355
references.citation: Rev Infect Dis. 1990 Sep-Oct;12 Suppl 7:S754-66
references.pmid: 2173105
references.citation: Transplantation. 2007 Dec 15;84(11):1534-9
references.pmid: 18091531
references.citation: Chest. 1999 Nov;116(5):1273-7
references.pmid: 10559086
references.citation: Kyobu Geka. 2007 Oct;60(11):982-7
references.pmid: 17926901
references.citation: Transplantation. 1993 Oct;56(4):1029-31
references.pmid: 8212185
references.citation: J Heart Lung Transplant. 1995 Mar-Apr;14(2):214-21
references.pmid: 7779838
references.citation: Clin Infect Dis. 1995 May;20(5):1346-53
references.pmid: 7620022
references.citation: Chest. 2004 Jan;125(1):165-72
references.pmid: 14718437
references.citation: Transplantation. 1999 Nov 27;68(10):1517-25
references.pmid: 10589949